RGTI
Rigetti Computing
-- 15.4400 NVDA
NVIDIA
-- 139.930 TSLA
Tesla
-- 454.130 LAES
SEALSQ Corp
-- 8.760 KULR
KULR Technology
-- 4.8000 
NEWS
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, will present preclinical data on INF904, their novel oral C5aR inhibitor, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) in Lübeck, Germany, from September 2-6, 2024. The company will showcase two poster presentations, participate in a C5a/C5aR-focused panel discussion, and speak at a satellite symposium.
INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has demonstrated anti-inflammatory effects in preclinical models. A first-in-human study showed that INF904 is well-tolerated and exhibits no safety concerns in single doses from 3 mg to 240 mg or multiple doses from 30 mg QD to 90 mg BID for 14 days. The drug achieved ≥90% blockade of C5a-induced neutrophil activation over the 14-day dosing period, supporting its potential as a best-in-class treatment.
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, will present preclinical data on INF904, their novel oral C5aR inhibitor, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) in Lübeck, Germany, from September 2-6, 2024. The company will showcase two poster presentations, participate in a C5a/C5aR-focused panel discussion, and speak at a satellite symposium.
INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has demonstrated anti-inflammatory effects in preclinical models. A first-in-human study showed that INF904 is well-tolerated and exhibits no safety concerns in single doses from 3 mg to 240 mg or multiple doses from 30 mg QD to 90 mg BID for 14 days. The drug achieved ≥90% blockade of C5a-induced neutrophil activation over the 14-day dosing period, supporting its potential as a best-in-class treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment